Serum Institute inks another vaccine dealUS Biotechnology company Novavax has entered a supply and license agreement with Serum Institute of India for the development and commercialization of its covid-19 vaccine candidate.
Serum Institute will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the “pandemic period" in all countries other than those designated by the World Bank as upper-middle or high-income countries.
On Tuesday, Novavax reported that its experimental covid-19 vaccine produced high levels of antibodies against the virus in a small, early-stage clinical trial, and that it could start a large pivotal phase 3 trial on humans in late September.